Dec 11, 2015
Myeloma Canada: Patient Handbook - Understanding Your Blood and Blood Tests
Myeloma Canada: Patient Handbook - Understanding Your Blood and Blood Tests https://myeloma.ca/pixms/uploads/serve/ckeditor/understanding...
109
Dec 11, 2015
Myeloma UK - Myeloma Animations Series: Clonal evolution: the changing nature of myeloma
Myeloma UK - Myeloma Animations Clonal evolution: the changing nature of myeloma Learn More: https://www.myeloma.org.uk/
116
Dec 10, 2015
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma A Phase 1 Study in Subjects With Relapsed or...
173
Dec 10, 2015
NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM
NCT02465060: phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas,...
176
Dec 10, 2015
FDA Approved for RRMM: Pomalidomide (Pomalyst) + Dexamethasone
April 23, 2015; SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it has fulfilled the accelerated...
89
Dec 9, 2015
NCT02519452: Phase 1 - Daratumumab + Recombinant Human Hyaluronidase (rHuPH20) RRMM - PAVO Study
MMY1004 (PAVO) Study RRMM The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and...
291
Dec 9, 2015
NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma
NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma Open-label, single-center, pilot study to assess the safety and feasibility...
141
Dec 9, 2015
Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
EMN12/HOVON129 Study Phase 2: To evaluate progression-free survival in adult pPCL patients by incorporation of carfilzomib and...
111
Dec 4, 2015
NCT02412878: Phase 3 - Once-weekly vs Twice-weekly Carfilzomib With Dexa in Relapsed MM (ARROW)
Phase 3 A.R.R.O.W. trial - ARROW Kd The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib...
271
Dec 3, 2015
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
GEM14 Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM Trial Studying...
272
Dec 1, 2015
NCT02514239: Phase 1 - Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Myeloma Patients
An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of...
192